Developing a novel combination immunotherapy for triple-negative breast cancer
开发针对三阴性乳腺癌的新型联合免疫疗法
基本信息
- 批准号:10734197
- 负责人:
- 金额:$ 66.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-18 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressBiological MarkersBreast Cancer PatientCCL2 geneCellsClinicalCombination immunotherapyCombined Modality TherapyDataDevelopmentGoalsImmuneImmune responseImmuno-ChemotherapyImmunocompetentImmunohistochemistryImmunologicsImmunotherapyKnowledgeMAPK8 geneMAPK9 geneMacrophageMalignant NeoplasmsMediatingMissionMyelogenousN-terminalNeoplasm MetastasisOutcomePaclitaxelPathway interactionsPatient-Focused OutcomesPatientsPersonsPhosphotransferasesPrediction of Response to TherapyProductionPrognosisProtein IsoformsPublic HealthRelapseResearchResistanceSamplingScientific Advances and AccomplishmentsSignal TransductionTestingTissue MicroarrayTumor TissueTumor-associated macrophagesWorkaggressive breast canceranti-PD1 antibodiesanticancer researchbiomarker identificationchemotherapyclinical translationclinically relevantcytokinehumanized mouseimmune checkpoint blockadeimmunoregulationimprovedkinase inhibitormalignant breast neoplasmmolecular subtypesmouse modelneoplastic cellneutrophilnovelnovel markerpatient derived xenograft modelpotency testingpre-clinicalpredictive markerrecruitresponseresponse biomarkersingle-cell RNA sequencingstandard of caresynergismtargeted agenttherapeutic biomarkertherapeutically effectivetreatment strategytriple-negative invasive breast carcinomatumortumor growthtumor microenvironmenttumor-immune system interactions
项目摘要
PROJECT SUMMARY
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and has a very poor
prognosis due to its tendency to metastasize and relapse. Immune checkpoint blockade (immunotherapy) plus
chemotherapy is the first-line treatment for metastatic TNBC, but the tumor responses are limited and not
durable. Additionally, the lack of robust predictive biomarkers of response remains a limiting factor in
maximizing the efficacy of immunotherapy. Therefore, there is an urgent need to develop a more effective
immunotherapy combination and establish novel biomarkers to identify TNBC patients who will benefit from
this treatment. Because the tumor microenvironment (TME) critically influences TNBC response to
immunotherapy, we set out to identify mechanisms that broadly mediate the immune response in TNBC. Our
preliminary studies showed that the c-Jun N-terminal kinase (JNK) pathway acts as a TME master switch in
promoting a persistent immunosuppressive TME in TNBC. Building on this evidence, our central hypothesis is
that JNK inhibitors (JNKi) synergize with immunotherapy by converting the TNBC TME from an
immunosuppressive to an immunoactive state. Our hypothesis will be tested through 3 specific aims: Aim 1)
Determine how JNK regulates the immunosuppressive TME and aggressiveness in TNBC; Aim 2) Establish
JNK signaling-related biomarkers of the immunosuppressive status of the TNBC TME; and Aim 3) Develop an
optimal JNKi-immunotherapy combination for TNBC. Completing these aims will provide a robust scientific
framework for developing effective therapeutic strategies for TNBC. The experimental approach will be as
follows: In Aim 1, we will investigate how JNK promotes TNBC aggressiveness by immunologically modulating
the TME using clinically relevant immunocompetent syngeneic TNBC mouse models with well-defined immune
TMEs. We will also identify molecules responsible for JNK’s immunological modulation of the TME. In Aim 2,
we will establish novel JNK signaling-related biomarkers reflecting the immunosuppressive status of the TNBC
TME using patient samples. In Aim 3, we will test whether JNKi synergize with immunotherapy in TNBC by
promoting an immunoactive TME, using clinically relevant immunocompetent syngeneic TNBC mouse models
and our established patient-derived xenografts of TNBC molecular subtypes (sensitive or resistant to
immunotherapy) in humanized mouse models. We expect to 1) generate sufficient preclinical data to support
the development of an effective JNKi-immunotherapy combination for patients with TNBC and 2) establish
biomarkers of the immunosuppressive status of the TNBC TME. The proposed research is significant because
it will fundamentally advance our understanding of mechanisms by which cancers promote suppression of the
response to immunotherapy and may lead to the development of a novel combination immunotherapy that
improves the survival of TNBC patients.
项目摘要
三阴性乳腺癌(TNBC)是乳腺癌中最具侵袭性的亚型,
由于其转移和复发的倾向,预后不良。免疫检查点阻断(免疫疗法)加
化疗是转移性TNBC的一线治疗,但肿瘤反应有限,
耐用.此外,缺乏可靠的反应预测生物标志物仍然是治疗的限制因素。
最大限度地提高免疫治疗的功效。因此,迫切需要制定一个更有效的
免疫疗法组合和建立新的生物标志物以鉴定将受益于免疫疗法组合的TNBC患者。
这种待遇。由于肿瘤微环境(TME)严重影响TNBC对肿瘤的反应,
在免疫疗法中,我们着手鉴定广泛介导TNBC中的免疫应答的机制。我们
初步研究表明,c-Jun N-末端激酶(JNK)途径在TME中起着主开关的作用,
促进TNBC中持续的免疫抑制性TME。基于这些证据,我们的核心假设是
JNK抑制剂(JNKi)通过将TNBC TME从一种免疫抑制剂转化为另一种免疫抑制剂而与免疫疗法协同作用。
免疫抑制至免疫活性状态。我们的假设将通过3个具体目标进行检验:目标1)
确定JNK如何调节TNBC中的免疫抑制性TME和侵袭性;目的2)建立
TNBC TME的免疫抑制状态的JNK信号传导相关的生物标志物;和目的3)开发一种用于TNBC TME的免疫抑制状态的JNK信号传导相关的生物标志物。
用于TNBC的最佳JNKi-免疫疗法组合。完成这些目标将提供一个强大的科学
为TNBC制定有效的治疗策略的框架。实验方法将作为
在目的1中,我们将研究JNK如何通过免疫调节来促进TNBC侵袭性,
TME使用具有明确免疫功能的临床相关免疫活性同系TNBC小鼠模型,
TME。我们还将鉴定负责JNK对TME的免疫调节的分子。在目标2中,
我们将建立新的JNK信号相关的生物标志物,反映TNBC的免疫抑制状态,
使用患者样本的TME。在目标3中,我们将通过以下方法测试JNKi是否与TNBC中的免疫疗法协同作用:
促进免疫活性TME,使用临床相关的免疫活性同基因TNBC小鼠模型
和我们建立的TNBC分子亚型的患者来源的异种移植物(对TNBC敏感或耐药),
免疫疗法)。我们希望1)产生足够的临床前数据来支持
为TNBC患者开发有效的JNKi-免疫治疗组合,以及2)建立
TNBC TME的免疫抑制状态的生物标志物。这项研究意义重大,因为
它将从根本上推进我们对癌症促进抑制肿瘤细胞增殖的机制的理解。
对免疫疗法的反应,并可能导致开发一种新的联合免疫疗法,
提高TNBC患者的生存率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Naoto T Ueno其他文献
Navigating the androgen receptor landscape in triple-negative breast cancer
在三阴性乳腺癌中探索雄激素受体领域
- DOI:
10.1016/s1470-2045(25)00029-4 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:35.900
- 作者:
Nithya Sridhar;Naoto T Ueno - 通讯作者:
Naoto T Ueno
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
III 期炎性乳腺癌 1 线与 2-3 线新辅助治疗后的临床结果。
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:3.8
- 作者:
F. Nakhlis;Samuel M. Niman;Naoto T Ueno;Elizabeth Troll;Sean J. Ryan;E. Yeh;Laura Warren;J. Bellon;Beth Harrison;T. Iwase;H. T. Carisa Le;S. Saleem;M. Teshome;Gary J. Whitman;Wendy A Woodward;Beth Overmoyer;S. Tolaney;M. Regan;F. Lynce;R. Layman - 通讯作者:
R. Layman
Naoto T Ueno的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Naoto T Ueno', 18)}}的其他基金
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
开发针对炎性乳腺癌肿瘤微环境的新疗法
- 批准号:
10836263 - 财政年份:2022
- 资助金额:
$ 66.49万 - 项目类别:
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
开发针对炎性乳腺癌肿瘤微环境的新疗法
- 批准号:
10390676 - 财政年份:2022
- 资助金额:
$ 66.49万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
8146139 - 财政年份:2007
- 资助金额:
$ 66.49万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
8265321 - 财政年份:2007
- 资助金额:
$ 66.49万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7630446 - 财政年份:2007
- 资助金额:
$ 66.49万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7252750 - 财政年份:2007
- 资助金额:
$ 66.49万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
7500877 - 财政年份:2007
- 资助金额:
$ 66.49万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7462422 - 财政年份:2007
- 资助金额:
$ 66.49万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
7894611 - 财政年份:2007
- 资助金额:
$ 66.49万 - 项目类别:
相似海外基金
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10490338 - 财政年份:2021
- 资助金额:
$ 66.49万 - 项目类别:
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10353104 - 财政年份:2021
- 资助金额:
$ 66.49万 - 项目类别:
Investigating pollution dynamics of swimming pool waters by means of chemical and biological markers
利用化学和生物标记物研究游泳池水体的污染动态
- 批准号:
21K04320 - 财政年份:2021
- 资助金额:
$ 66.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10688286 - 财政年份:2021
- 资助金额:
$ 66.49万 - 项目类别:
Novel biological markers for immunotherapy and comprehensive genetic analysis in thymic carcinoma
用于胸腺癌免疫治疗和综合遗传分析的新型生物标志物
- 批准号:
20K17755 - 财政年份:2020
- 资助金额:
$ 66.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10578649 - 财政年份:2019
- 资助金额:
$ 66.49万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10295141 - 财政年份:2019
- 资助金额:
$ 66.49万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10041708 - 财政年份:2019
- 资助金额:
$ 66.49万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
9776149 - 财政年份:2019
- 资助金额:
$ 66.49万 - 项目类别:
Combining biological and non-biological markers to develop a model predictive of treatment response for individuals with depression
结合生物和非生物标志物来开发预测抑郁症患者治疗反应的模型
- 批准号:
2063934 - 财政年份:2018
- 资助金额:
$ 66.49万 - 项目类别:
Studentship